<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637919</url>
  </required_header>
  <id_info>
    <org_study_id>IN_HFM_102</org_study_id>
    <nct_id>NCT04637919</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of High-dose IN-B001 After Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and immunogenicity of high-dose IN-B001 after&#xD;
      administration in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enterovirus 71(EV71) and coxsackievirus A16(CVA16) are major causes of Hand-foot-and-mouth&#xD;
      disease (HFMD) occurring in pediatric population. Although EV71 vaccine has been licensed in&#xD;
      China, vaccine for CVA16-associated HFMD is currently not available anywhere. The purpose of&#xD;
      this phase I study is to evaluate the safety and immunogenicity of EV71/CVA16 bivalent&#xD;
      vaccine in healthy adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events of IN-B001 (Safety of IN-B001)</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Frequency and severity of adverse events up to 32 weeks post first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of IN-B001: Anti-EV71 IgG titer</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Serum EV71-specific IgG titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of IN-B001 : Anti-CVA16 IgG titer</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Serum CVA16-specific IgG titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of IN-B001 : Geometric mean titer (GMT) of EV71 neutralizing antibody titers</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against EV71</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of IN-B001 : GMT of CVA16 neutralizing antibody titers</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against CVA16</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hand, Foot and Mouth Disease</condition>
  <arm_group>
    <arm_group_label>IN-B001 EV71 A dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN-B001 CVA16 B dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated CVA16 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN-B001 Bivalent C dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated EV71/CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IN-B001 EV71 A dose</intervention_name>
    <description>Inactivated vaccine against EV71, three doses, 28 days interval</description>
    <arm_group_label>IN-B001 EV71 A dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IN-B001 CVA16 B dose</intervention_name>
    <description>Inactivated vaccine against CVA16, three doses, 28 days interval</description>
    <arm_group_label>IN-B001 CVA16 B dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IN-B001 Bivalent C dose</intervention_name>
    <description>Inactivated vaccine against EV71/CVA16, three doses, 28 days interval</description>
    <arm_group_label>IN-B001 Bivalent C dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, three doses, 28 days interval</description>
    <arm_group_label>IN-B001 Bivalent C dose</arm_group_label>
    <arm_group_label>IN-B001 CVA16 B dose</arm_group_label>
    <arm_group_label>IN-B001 EV71 A dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult aged ≥19 to &lt;50 years at the time of screening tests&#xD;
&#xD;
          -  Body mass index(BMI) of ≥18.0 kg/m2 to ≤27.0 kg/m2, with body weight of ≥55.0 kg to&#xD;
             ≤90.0 kg for men and ≥50.0 kg to ≤90.0 kg for women at the time of screening tests&#xD;
&#xD;
          -  Determined by the investigator to be eligible for study participation based on the&#xD;
             results of screening tests&#xD;
&#xD;
          -  Intact deltoid muscle that allows administration of the investigational product&#xD;
&#xD;
          -  Consent to use medically acceptable contraception throughout the study&#xD;
&#xD;
          -  Negative finding from a pregnancy test (urine hCG) at the time of the screening for&#xD;
             women of childbearing potential&#xD;
&#xD;
          -  Voluntary decision and provision of written consent on participation in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of a hand-foot-mouth disease or history of a disease related with&#xD;
             enterovirus(EV) infection within 3 months prior to the 1st IP administration&#xD;
&#xD;
          -  Medical history of an anaphylactic or similar acute reaction to IN-B001 or similar&#xD;
             vaccine&#xD;
&#xD;
          -  Febrile disease or infectious disease within 2 weeks prior to the 1st IP&#xD;
             administration&#xD;
&#xD;
          -  Whole blood donation within 2 months or apheresis within 1 month prior to the 1st IP&#xD;
             administration&#xD;
&#xD;
          -  Vaccination with other prevention vaccine within 2 months prior to the 1st IP&#xD;
             administration&#xD;
&#xD;
          -  Use of an immunomodulator or immunosuppressant within 3 months prior to the 1st IP&#xD;
             administration&#xD;
&#xD;
          -  History of a Guillain Barre syndrome&#xD;
&#xD;
          -  Excessive caffeine intake or continuous alcohol consumption or incapable of abstention&#xD;
             from alcohol during the study&#xD;
&#xD;
          -  Participation in other clinical trial within 6 months prior to the 1st IP&#xD;
             administration&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Clinically significant hepatic, renal, neurological, respiratory, endocrine,&#xD;
             hematology and oncology, cardiovascular, urological or psychiatric disease or such&#xD;
             history&#xD;
&#xD;
          -  Positive serological finding (type B hepatitis test, type C hepatitis test, human&#xD;
             immunodeficiency virus(HIV) test)&#xD;
&#xD;
          -  History of drug abuse or positive finding from a urine screening test for an abusive&#xD;
             drug&#xD;
&#xD;
          -  Use or of any prescription medication or oriental medicine within 2 weeks or any&#xD;
             over-the-counter(OTC) medication, health functional food or vitamin within 1 week&#xD;
             prior to the 1st IP administration or expected use of such products&#xD;
&#xD;
          -  Administration of a blood product or blood-derived agent within 3 months prior to the&#xD;
             1st IP administration&#xD;
&#xD;
          -  Determined by the investigator to be ineligible for study participation due to other&#xD;
             reason including clinical laboratory findings&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naree Shin, MS</last_name>
    <phone>+82-2-6477-0271</phone>
    <email>naree.shin@inno-n.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital, Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <phone>+82-2-2072-1910</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot-and-Mouth Disease</mesh_term>
    <mesh_term>Hand, Foot and Mouth Disease</mesh_term>
    <mesh_term>Mouth Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

